Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Clinical trial NCT05224141 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05224141
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-24
- Primary completion
- 2024-06-04
- Enrollment
- 460
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.